Nutrition & mushrooms 2025

Ganoderma lucidum spore oil and triglyceride reduction: a randomized double-blind trial in dyslipidemia

An RCT in 110 participants with dyslipidemia: G. lucidum spore oil over 12 weeks significantly lowered total cholesterol, triglycerides and LDL-C and raised HDL-C versus placebo. No renal adverse effects; hepatic function markers actually improved in the active group.

Nutrients 2025. Clinical Evaluation of Ganoderma lucidum Spore Oil for Triglyceride Reduction: A Randomized, Double-Blind, Crossover Study (PMID 40077714).

Rationale

Dyslipidemia is a modifiable cardiovascular risk factor. Triterpenoids of reishi spore oil (GLSO) showed hypolipidemic activity in preclinical work; the authors ran the first systematic clinical evaluation of GLSO efficacy and safety in people with dyslipidemia.

Methods

A randomized double-blind placebo-controlled trial (crossover per the title). 110 participants with dyslipidemia were assigned to GLSO extract or placebo for 12 weeks. Baseline groups were comparable by age and sex (χ² test). Outcomes: lipid panel (TC, TG, LDL-C, HDL-C) plus hepatic and renal safety markers.

Results

  • After 12 weeks, the GLSO group vs placebo: total cholesterol, triglycerides and LDL-C significantly lower, HDL-C significantly higher — all differences statistically significant.
  • Relative changes in lipid parameters also differed significantly between groups.
  • Safety: no effect on renal markers; hepatic markers in the active group improved — a favorable tolerability profile.

Conclusions

The authors conclude that GLSO extract improves the lipid profile and liver function with good tolerability and support its clinical use in dyslipidemia.

Caveats

  • This is spore oil, not fruiting body or a polysaccharide extract: results cannot be extrapolated to any "reishi capsule" — the bioactive profile of spore oil differs (triterpenoids vs β-glucans).
  • The result is unusually strong for a single RCT — all four lipid parameters significant at once; until independent replication this is a single signal, not an established fact.
  • Context matters: the 2015 Cochrane review (PMID 25686270) found insufficient evidence for reishi's effects on cardiovascular risk factors overall — this new work does not overturn the general skepticism but defines a precise replication target: GLSO specifically.
  • This card replaces an unverifiable citation about an "8-week trial of a combined reishi+shiitake extract (Abidin, Phytomedicine 2018)" — no such work exists in PubMed.